COVID-19 Associated Endothelial Dysfunction Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-22

Study Completion Date

2022-12-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

SARS-CoV-2 enters human cells through the binding of the spike protein with angiotensin converting enzyme-2 (ACE2), a membrane receptor highly expressed in immune or non-immune cells, and in many organs, including lungs and endothelial cells.

In COVID-19 disease, the infection of endothelial might cause an acute endothelial dysfunction.

The objective of this study is to demonstrate that patients COVID19 (+) hospitalized in ICU present an acute endothelial dysfunction (compared with COVID19 (-) also hospitalized in ICU).

This acute endothelial dysfunction could lead to organ failure, systemic immune dysregulation and thrombosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Active Screening of Arterial Hypertension by Community Outreach Workers in the Cayenne Metropolitan Area to Reduce the Incidence of Cardiovascular Disease

NCT05814068

High Blood Pressure

UNKNOWN NA

Covid-19 Patients With Hypertension and/or Kidney Diseases

NCT05465772

COVID-19 Hypertension Kidney Diseases

UNKNOWN

Pulmonary Artery Pressure in COVID-19 Survivors

NCT05993338

Pulmonary Hypertension Secondary

COMPLETED NA

Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial

NCT04332666

Coronavirus Respiratory Failure Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere +1 more

UNKNOWN PHASE2/PHASE3

Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection

NCT04354610

COVID 19

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This cohort study compares 3 exposure cohorts :

Cohort C1 includes COVID19 (+) patients admitted in ICU in whom the diagnosis of COVID19 pneumonia was confirmed.

Cohort C2 includes COVID 19 (-) matched patients also admitted in ICU.

Cohort C3 is a control group. Patients with few comorbidities, ASA 1, recruited during preoperative assessment for elective surgery.

Eligible patients are included within 72 hours of ICU admission (C1, C2) or during the preoperative assessment (C3). Oral consent is needed after complete explanation of the protocol.

During inclusion visit (V0), patient characteristics as treatments, medical history, clinical and biological data are registered.

Microcirculation is assessed for each patient directly after inclusion.

For patients in C1 and C2 a follow-up is planned. This visit (V1) occurs when the patient is discharged from ICU or the day of his death if it occurs in ICU. In case of prolonged stay in ICU, V1 is carried out 2 months after inclusion. During V1, arterial and/or venous thromboembolic events and mortality in ICU is registered.

For Patients in C3, no follow-up is planned.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Microcirculation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort C1

COVID19 (+) ICU patients with COVID19 pneumonia.

Group Type OTHER

Procedure : Multimodal microvascular assessment at study inclusion

Intervention Type DIAGNOSTIC_TEST

* Vascular occlusion test (VOT) performed on the arm. Measurement of the quality of tissue reperfusion by NIRS on the thenar eminence and the digital perfusion index.
* Microcirculation reactivity is measured for each patient with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of microvascular reactivity: Acetylcholine and Nitroprusside Iontophoresis.
* Morphological analysis of the microcirculation by sublingual videomicroscopy.

Cohort C2

COVID19 (-) matched ICU patients

Group Type OTHER

Procedure : Multimodal microvascular assessment at study inclusion

Intervention Type DIAGNOSTIC_TEST

* Vascular occlusion test (VOT) performed on the arm. Measurement of the quality of tissue reperfusion by NIRS on the thenar eminence and the digital perfusion index.
* Microcirculation reactivity is measured for each patient with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of microvascular reactivity: Acetylcholine and Nitroprusside Iontophoresis.
* Morphological analysis of the microcirculation by sublingual videomicroscopy.

Cohort C3

COVID19 (-) ASA 1 non-hospitalized patients

Group Type OTHER

Procedure : Multimodal microvascular assessment at study inclusion

Intervention Type DIAGNOSTIC_TEST

* Vascular occlusion test (VOT) performed on the arm. Measurement of the quality of tissue reperfusion by NIRS on the thenar eminence and the digital perfusion index.
* Microcirculation reactivity is measured for each patient with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of microvascular reactivity: Acetylcholine and Nitroprusside Iontophoresis.
* Morphological analysis of the microcirculation by sublingual videomicroscopy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Procedure : Multimodal microvascular assessment at study inclusion

* Vascular occlusion test (VOT) performed on the arm. Measurement of the quality of tissue reperfusion by NIRS on the thenar eminence and the digital perfusion index.
* Microcirculation reactivity is measured for each patient with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of microvascular reactivity: Acetylcholine and Nitroprusside Iontophoresis.
* Morphological analysis of the microcirculation by sublingual videomicroscopy.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient (≥ 18 ans)
* Affiliation to the French National Healthcare System
* Voluntary patient who have given oral consent

Cohort C1, COVID19 (+) patients hospitalized in ICU :

* Patient admitted to ICU within 72 hours before inclusion
* Patient presenting SARS-COV2 pneumonia diagnosed by CT scan or by COVID-19 PCR test.

Cohort C2, COVID19 (-) patients hospitalized in ICU :

* Patient admitted to ICU within 72 hours before inclusion
* All COVID19 PCR tests carried out in the 15 days prior inclusion are negative
* All the CT scans possibly performed since the acute event do not show COVID19 pulmonary lesions
* Matching with the cases C1 COVID 19 (+) patients on sex, age (threshold at 65 years), treated hypertension, treated diabetes mellitus.

Cohort C3, elective surgery patients who are not hospitalized in ICU :

* ASA 1 classification (no major comorbidity, a normaly healthy patient)
* Asymptomatic to COVID19 according to French Anesthesiology Society 2020 :

* No major symptoms among : measured fever \> 38°C, dry cough, shortness of breath or high respiratory rate (\>20/min), anosmia, ageusia
* No more than one minor symptom among : sore throat, rhinorrhea, chest pain, myalgia, general alteration or severe tiredness, confusion, disorientation, headache, diarrhea, nausea or/and vomiting, rash/ frostbite/cracking on fingers or hand
* No positive COVID19 PCR test within 15 days prior to inclusion

* Proven sepsis (Procalcitonin \>1.0 µg/l) in the 24 hours prior to inclusion
* End-stage kidney disease with dialysis
* Patient with haemodynamic failure treated by norepinephrine
* Patient with traumatic brain injury
* Intubated patient and/or sedated
* Pregnant woman, parturient and nursing mother
* Person restricted in liberty by an administrative or judicial decision
* Patient concerned with admission for psychiatric care
* Adult person subject to a legal protection measure or unable to express consent